Tokyo Tape
Sign in
← Otsuka Holdings

Half-year report · Q2

4578.TEDINET S100U5FO
Period2024-01-01 → 2024-06-30
Filed2024-08-02
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 56
MetricValuePeriodScopeSource row
Revenue¥1.11T2024-01-01 → 2024-06-30Cons.Revenue IFRS
Revenue¥589.4bn2024-04-01 → 2024-06-30dCons.Revenue IFRS
Revenue¥2.02T2023-01-01 → 2023-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥947.5bn2023-01-01 → 2023-06-30Cons.Revenue IFRS
Revenue¥499.2bn2023-04-01 → 2023-06-30dCons.Revenue IFRS
Operating income¥126.3bn2024-01-01 → 2024-06-30Cons.Operating profit loss IFRS
Operating income¥34.3bn2024-04-01 → 2024-06-30dCons.Operating profit loss IFRS
Operating income¥130.7bn2023-01-01 → 2023-06-30Cons.Operating profit loss IFRS
Operating income¥53.9bn2023-04-01 → 2023-06-30dCons.Operating profit loss IFRS
Profit before tax¥142.2bn2024-01-01 → 2024-06-30Cons.Profit loss before tax IFRS
Profit before tax¥42.1bn2024-04-01 → 2024-06-30dCons.Profit loss before tax IFRS
Profit before tax¥142.7bn2023-01-01 → 2023-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥138.8bn2023-01-01 → 2023-06-30Cons.Profit loss before tax IFRS
Profit before tax¥59.6bn2023-04-01 → 2023-06-30dCons.Profit loss before tax IFRS
Net income (owners)¥107.8bn2024-01-01 → 2024-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥30.4bn2024-04-01 → 2024-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥121.6bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥102.6bn2023-01-01 → 2023-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥41.2bn2023-04-01 → 2023-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥110.6bn2024-01-01 → 2024-06-30Cons.Profit loss IFRS
Net income¥31.7bn2024-04-01 → 2024-06-30dCons.Profit loss IFRS
Net income¥105.1bn2023-01-01 → 2023-06-30Cons.Profit loss IFRS
Net income¥42.4bn2023-04-01 → 2023-06-30dCons.Profit loss IFRS
Total assets¥3.66Tat 2024-06-30Cons.Assets IFRS
Total assets¥3.36Tat 2023-12-31Cons.Assets IFRS
Total assets¥3.31Tat 2023-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥993.9bnat 2024-06-30Cons.Liabilities IFRS
Total liabilities¥924.9bnat 2023-12-31Cons.Liabilities IFRS
Net assets / equity¥2.67Tat 2024-06-30Cons.Equity IFRS
Net assets / equity¥2.44Tat 2023-12-31Cons.Equity IFRS
Net assets / equity¥2.47Tat 2023-06-30Cons.Equity IFRS
Net assets / equity¥2.26Tat 2022-12-31dCons.Equity IFRS
Equity (owners)¥2.62Tat 2024-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.39Tat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.43Tat 2023-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥485.9bnat 2024-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥513.3bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥498.7bnat 2023-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥471.6bnat 2022-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥133.0bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥283.2bn2023-01-01 → 2023-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥113.5bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥159.2bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥190.5bn2023-01-01 → 2023-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥54.3bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥26.2bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥60.3bn2023-01-01 → 2023-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥46.8bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥198.612024-01-01 → 2024-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥56.032024-04-01 → 2024-06-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥224.12023-01-01 → 2023-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥189.062023-01-01 → 2023-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥75.852023-04-01 → 2023-06-30dCons.Basic earnings loss per share IFRS
Equity ratio71.6%at 2024-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.2%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio73.4%at 2023-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 88
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2024-01-01 → 2024-06-30¥56.5bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2024-04-01 → 2024-06-30¥29.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2024-01-01 → 2024-06-30¥54.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2024-04-01 → 2024-06-30¥28.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2024-01-01 → 2024-06-30¥1.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2024-04-01 → 2024-06-30¥880m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2024-01-01 → 2024-06-30¥4.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2024-04-01 → 2024-06-30¥2.9bn
Reconciling Itemsreconcilingrevenue2024-01-01 → 2024-06-30−¥1.8bn
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-06-30−¥890m
Reconciling Itemsreconcilingrevenue intersegment2024-01-01 → 2024-06-30−¥1.8bn
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-06-30−¥890m
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-06-30−¥24.2bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-06-30−¥13.4bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue2024-01-01 → 2024-06-30¥15.7bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue2024-04-01 → 2024-06-30¥8.4bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue external2024-01-01 → 2024-06-30¥15.7bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue external2024-04-01 → 2024-06-30¥8.4bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue intersegment2024-01-01 → 2024-06-30¥3m
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue intersegment2024-04-01 → 2024-06-30¥1m
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentsegment profit2024-01-01 → 2024-06-30¥12.3bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentsegment profit2024-04-01 → 2024-06-30¥8.0bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue2024-01-01 → 2024-06-30¥271.8bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue2024-04-01 → 2024-06-30¥145.6bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue external2024-01-01 → 2024-06-30¥271.8bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue external2024-04-01 → 2024-06-30¥145.6bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2024-01-01 → 2024-06-30¥15m
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2024-04-01 → 2024-06-30¥8m
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentsegment profit2024-01-01 → 2024-06-30¥37.3bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentsegment profit2024-04-01 → 2024-06-30¥20.5bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentrevenue2024-01-01 → 2024-06-30¥766.7bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentrevenue2024-04-01 → 2024-06-30¥407.1bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentrevenue external2024-01-01 → 2024-06-30¥766.7bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentrevenue external2024-04-01 → 2024-06-30¥407.1bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentsegment profit2024-01-01 → 2024-06-30¥96.0bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentsegment profit2024-04-01 → 2024-06-30¥16.2bn
—segment totalrevenue2024-01-01 → 2024-06-30¥1.11T
—segment totalrevenue2024-04-01 → 2024-06-30¥590.3bn
—segment totalrevenue external2024-01-01 → 2024-06-30¥1.11T
—segment totalrevenue external2024-04-01 → 2024-06-30¥589.4bn
—segment totalrevenue intersegment2024-01-01 → 2024-06-30¥1.8bn
—segment totalrevenue intersegment2024-04-01 → 2024-06-30¥890m
—segment totalsegment profit2024-01-01 → 2024-06-30¥150.5bn
—segment totalsegment profit2024-04-01 → 2024-06-30¥47.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-01-01 → 2023-06-30¥55.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-06-30¥27.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-01-01 → 2023-06-30¥53.5bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-06-30¥26.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-01-01 → 2023-06-30¥1.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-06-30¥920m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-01-01 → 2023-06-30¥4.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-06-30¥1.5bn
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-06-30−¥1.7bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-06-30−¥965m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-06-30−¥1.7bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-06-30−¥965m
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-06-30−¥25.4bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-06-30−¥12.4bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue2023-01-01 → 2023-06-30¥17.4bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue2023-04-01 → 2023-06-30¥9.2bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue external2023-01-01 → 2023-06-30¥17.4bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue external2023-04-01 → 2023-06-30¥9.2bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue intersegment2023-01-01 → 2023-06-30¥9m
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥4m
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentsegment profit2023-01-01 → 2023-06-30¥8.1bn
jpcrp040300-q2r_E21183-000Consumer Productsreportable segmentsegment profit2023-04-01 → 2023-06-30¥5.8bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue2023-01-01 → 2023-06-30¥226.2bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue2023-04-01 → 2023-06-30¥122.2bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue external2023-01-01 → 2023-06-30¥226.2bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue external2023-04-01 → 2023-06-30¥122.2bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2023-01-01 → 2023-06-30¥54m
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥40m
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentsegment profit2023-01-01 → 2023-06-30¥7.0bn
jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segmentsegment profit2023-04-01 → 2023-06-30−¥3.8bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentrevenue2023-01-01 → 2023-06-30¥650.4bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentrevenue2023-04-01 → 2023-06-30¥340.9bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentrevenue external2023-01-01 → 2023-06-30¥650.4bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentrevenue external2023-04-01 → 2023-06-30¥340.9bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentsegment profit2023-01-01 → 2023-06-30¥136.3bn
jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segmentsegment profit2023-04-01 → 2023-06-30¥62.7bn
—segment totalrevenue2023-01-01 → 2023-06-30¥949.2bn
—segment totalrevenue2023-04-01 → 2023-06-30¥500.2bn
—segment totalrevenue external2023-01-01 → 2023-06-30¥947.5bn
—segment totalrevenue external2023-04-01 → 2023-06-30¥499.2bn
—segment totalrevenue intersegment2023-01-01 → 2023-06-30¥1.7bn
—segment totalrevenue intersegment2023-04-01 → 2023-06-30¥965m
—segment totalsegment profit2023-01-01 → 2023-06-30¥156.1bn
—segment totalsegment profit2023-04-01 → 2023-06-30¥66.3bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 877
ItemContextValueUnit
Finance costs IFRSCurrentYTDDuration4665000000JPY
Profit loss before tax IFRSPrior1YTDDuration138833000000JPY
Profit loss before tax IFRSCurrentYTDDuration142195000000JPY
Income tax expense IFRSPrior1YTDDuration33774000000JPY
Income tax expense IFRSCurrentYTDDuration31570000000JPY
Profit loss IFRSPrior1YTDDuration105058000000JPY
Profit loss IFRSCurrentYTDDuration110625000000JPY
Profit loss attributable to owners of parent IFRSPrior1YTDDuration102594000000JPY
Profit loss attributable to owners of parent IFRSCurrentYTDDuration107795000000JPY
Profit loss attributable to non controlling interests IFRSPrior1YTDDuration2464000000JPY
Profit loss attributable to non controlling interests IFRSCurrentYTDDuration2829000000JPY
Profit loss IFRSPrior1YTDDuration105058000000JPY
Profit loss IFRSCurrentYTDDuration110625000000JPY
Basic earnings loss per share IFRSPrior1YTDDuration189.06
Basic earnings loss per share IFRSCurrentYTDDuration198.61
Diluted earnings loss per share IFRSPrior1YTDDuration－
Diluted earnings loss per share IFRSCurrentYTDDuration－
Revenue IFRSPrior1QuarterDuration499193000000JPY
Revenue IFRSCurrentQuarterDuration589412000000JPY
Cost of sales IFRSPrior1QuarterDuration151086000000JPY
Cost of sales IFRSCurrentQuarterDuration164409000000JPY
Gross profit IFRSPrior1QuarterDuration348106000000JPY
Gross profit IFRSCurrentQuarterDuration425002000000JPY
Selling general and administrative expenses IFRSPrior1QuarterDuration196725000000JPY
Selling general and administrative expenses IFRSCurrentQuarterDuration239971000000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1QuarterDuration4119000000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentQuarterDuration11187000000JPY
Research and development expenditure recognized as expense during period IFRSPrior1QuarterDuration74134000000JPY
Research and development expenditure recognized as expense during period IFRSCurrentQuarterDuration71561000000JPY
Impairment losses pl IFRSPrior1QuarterDuration28718000000JPY
Impairment losses pl IFRSCurrentQuarterDuration103951000000JPY
Other income IFRSPrior1QuarterDuration1731000000JPY
Other income IFRSCurrentQuarterDuration13781000000JPY
Other expenses IFRSPrior1QuarterDuration467000000JPY
Other expenses IFRSCurrentQuarterDuration228000000JPY
Operating profit loss IFRSPrior1QuarterDuration53911000000JPY
Operating profit loss IFRSCurrentQuarterDuration34258000000JPY
Finance income IFRSPrior1QuarterDuration6868000000JPY
Finance income IFRSCurrentQuarterDuration10488000000JPY
Finance costs IFRSPrior1QuarterDuration1189000000JPY
Finance costs IFRSCurrentQuarterDuration2630000000JPY
Profit loss before tax IFRSPrior1QuarterDuration59590000000JPY
Profit loss before tax IFRSCurrentQuarterDuration42116000000JPY
Income tax expense IFRSPrior1QuarterDuration17195000000JPY
Income tax expense IFRSCurrentQuarterDuration10387000000JPY
Profit loss IFRSPrior1QuarterDuration42395000000JPY
Profit loss IFRSCurrentQuarterDuration31728000000JPY
Profit loss attributable to owners of parent IFRSPrior1QuarterDuration41163000000JPY
Profit loss attributable to owners of parent IFRSCurrentQuarterDuration30418000000JPY
Profit loss attributable to non controlling interests IFRSPrior1QuarterDuration1231000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-12-31pass rounding
balance sheet identityconsolidated 2024-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-06-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-06-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2024-01-01/2024-06-30pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-06-30pass